Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Histone deacetylase 6 (HDAC6) is a protein known to be involved in a wide array of cancers. Although there are currently 4 approved HDAC inhibitors to date, these drugs lack the selectivity to only target HDAC6, given its high structural similarities with 10 other HDAC proteins, resulting in severe side-effects in patients such as nausea, diarrhea, and cardiac toxicities. Moreover, these approved drugs are also easily eliminated by the body, requiring the patients to take high doses frequently, further worsening the toxicity profile. To mitigate these drawbacks, we have developed >500 molecules with exceptional potency, HDAC6-selectivity, and stability. With promising efficacy in cancer cell models, the next aim of our research is to evaluate the stability of these compounds. We hope to use the pharmacokinetics profiles obtained to guide the development of stable, effective and safe molecules as the next generation of disease-modifying treatment for T-cells prolymphocytic leukaemia.
Patrick Gunning
Nabanita Nawar
Incubate Innovate Network of Canada
Chemistry
Professional, scientific and technical services
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.